🕒 Last update: loading…22/11/2026

Stock CureVac N.V. 5CV.DE

CureVac N.V. — Investlytic score 2/5 on the five criteria.

-
-
40/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 2/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ✅ Debt passed
  • ✅ P/E passed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2020 → 2021: -58.43%

Price change 2021 → 2022: -81.23%

Price change 2022 → 2023: -32.22%

Price change 2023 → 2024: -21.56%

Price change 2024 → 2025: 19.87%

Price change 2025 → 2026: 7.46%

Price change 2026 (year to date): 0.26%

Financial growth

Revenue CAGR (7 years): 86.13%

Earnings CAGR (7 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 0.06

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 4.50

P/E < 25.0 (maximum threshold).

Correction (6 months)

Price history over 6 months not available.

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…
03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Dividends and earnings

CureVac N.V.: dividend history, last distributions, stock splits and earnings releases.

No known dividend for this company.

Earnings releases

DatePublished EPSExpected EPSSurprise
15/08/2025-0.26-0.18n/a
20/05/2025-0.23-0.18n/a
10/04/2025-0.15-0.21n/a
12/11/20241.511.41+7.1 %
15/08/2024-0.32-0.28n/a
23/05/2024-0.31-0.20n/a

Factual data: ex-dividend history and earnings calendar, as of 21/11/2026. A past dividend does not guarantee the next one.

+

PEA and practical information

PEA eligibility
likely
head office in the EU or EEA, listed on a European exchange
Listing exchange
Xetra
IPO: 25/08/2020
ISIN code
NL0015436031
Workforce
825
full-time employees
Chief executive
Alexander Zehnder

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about CureVac N.V.

Is CureVac N.V. stock eligible for the French PEA?

Likely: the company is headquartered in the European Union or the European Economic Area (ISIN NL0015436031) and the stock is listed on a European exchange. The institution holding the PEA confirms eligibility.

How many employees does CureVac N.V. have?

825 full-time employees according to the latest published profile.

Who runs CureVac N.V.?

Alexander Zehnder is the company's chief executive.